JOURNAL BACTERIOLOGY, Aug. 2002, p. 4555â€“4572                                                                                Vol. 184,  16
0021-9193/02/$04.00â«¹0 DOI: 10.1128/JB.184.16.4555â€“4572.2002
Copyright Â© 2002, American Society Microbiology. Rights Reserved.



  Genetic Footprinting Antimicrobial Drug Targets: Examples
                 Cofactor Biosynthetic Pathways
             Svetlana Y. Gerdes, Michael D. Scholle, Mark Dâ€™Souza, Axel Bernal, Mark V. Baev,
                   Michael Farrell, Oleg V. Kurnasov, Matthew D. Daugherty, Faika Mseeh,
                          Boris M. Polanuyer, John W. Campbell, Shubha Anantha,
                             Konstantin Y. Shatalin, Shamim  K. Chowdhury,
                               Michael Y. Fonstein, Andrei L. Osterman*
                                            Integrated Genomics , Chicago, Illinois 60612
                                              Received 17 January 2002/Accepted 14 2002

             Novel drug targets required order design new defenses antibiotic-resistant pathogens.
          Comparative genomics provides new opportunities finding optimal targets previously unexplored
          cellular functions, based understanding related biological processes bacterial pathogens           hosts. integrated approach identification prioritization broad-spectrum drug targets.
          strategy based genetic footprinting Escherichia coli followed metabolic context analysis           essential gene orthologs various species. Genes required viability E. coli rich medium identified
          genome scale using genetic footprinting technique. Potential target pathways deduced           data compared panel representative bacterial pathogens using metabolic reconstructions
          genomic data. Conserved indispensable functions revealed analysis potentially represent
          broad-spectrum antibacterial targets. target prioritization involves comparison corresponding
          pathways individual functions pathogens human host. promising targets           validated direct knockouts model pathogens. efficacy approach illustrated using examples
          metabolism adenylate cofactors NAD(P), coenzyme  flavin adenine dinucleotide. drug
          targets pathways, including distantly related adenylyltransferases (orthologs E. coli
          genes nadD, coaD, ribF), discussed 


  growing number antibiotic-resistant microbial patho-                  scale high-throughput random transposon mutagenesis. gens (44, 46; http://www.cdc.gov/narms/default.htm) presents                 major advantage technique parallel analysis challenge modern medicine. majority existing                 thousands genes multiple growth conditions.
antibiotics utilize limited number core chemical structures                  transposon-based approach termed â€œgenetic footprintingâ€? target cellular functions, cell wall bio-               originally described Saccharomyces cerevisiae (84, 85).
synthesis, DNA replication, transcription, translation (67).               Genetic footprinting step process:   random trans-
Identification unexplored cellular functions potential tar-              poson mutagenesis large number cells, (ii) competitive
gets prerequisite development novel antibiotic che-                outgrowth mutagenized population various selec-
motypes. Choosing optimal target function crucial step                 tive conditions, (iii) analysis individual mutants surviv- long expensive process drug development                      ing population using direct sequencing various hy-
requires best possible understanding related biological                 bridization PCR-based techniques. Various modifications
processes bacterial pathogens hosts.                              genetic footprinting recently applied   Extensive programs utilizing genomic information search                   microorganisms, including Mycoplasma genitalium Myco- novel antimicrobial targets launched recently                 plasma pneumoniae (49), Pseudomonas aeruginosa (99), Heli-
industry academia (14, 15, 69, 72, 91). Complete genome                    cobacter pylori (52), Escherichia coli (7, 45). ver-
sequences multiple bacterial species, including major                  sion method, termed genomic analysis mapping pathogens, available years,                   vitro transposition, developed Haemophilus projects way (16). abundance                       influenzae (1, 75) Streptococcus pneumoniae (1). Direct
genomic data enabled development novel post-                        application technique usually limited microbial
genomic experimental computational techniques aimed                     species natural competence, transposon mutagene-
drug target discovery. Experimental approaches genome-                      sis performed vitro isolated DNA fragments, wide identification genes essential cell viability           mutations introduced genome transformation
microbial species reviewed recently (23, 43, 54, 59,                 linear DNA fragments followed gene conversion. 67, 77, 79). techniques based systematic                   targeting specific genomic region, approach increases
gene inactivation directed mutagenesis genome                    insertion density, improving resolution genetic footprinting.
                                                                               elegant extension method naturally compe-
  * Corresponding author. Mailing address: Integrated Genomics, ,
                                                                               tent species described P. aeruginosa (99).
2201 W. Campbell Park Dr., Chicago, 60612. Phone: (312) 491-0846,              Genetic footprinting E. coli mini-Tn10 mutagenesis ext. 213. Fax: (312) 491-0856. E-mail: andrei@integratedgenomics.com.          vivo recently reported (7, 45). systematic

                                                                        4555
 4556      GERDES ET AL.                                                                                                                           J. BACTERIOL.


analysis E. coli gene essentiality, chosen ap-                       Transposome        formation       transposon      mutagenesis.     Plasmid
proach based use â€œtransposome,â€? precut trans-                     pMODâ¬?MCSâ¬Ž containing artificial transposon EZ::TNâ¬?KAN-2â¬Ž (Epicentre
                                                                                Technologies, Madison, Wis.) isolated strain (MG1655 poson DNA stable complex modified Tn5 transposase                     DH10B) subsequently mutagenized avoid restriction-modification
(40, 47). approach advantages mini-Tn10                   problems. Transposon DNA released PvuII digestion, recommended
mutagenesis:   single irreversible insertions pro-                   manufacturer, gel purified using QIAquick gel extraction columns
duced, source transposase activity pro-                (Qiagen, Valencia, Calif.). Transposomes preformed incubating trans-
                                                                                poson DNA (7 ng/â?®l) hyperactive Tn5 EZ::TN transposase (0.1 U/â?®l;
tein transposome complex; (ii) need                                                                                 Epicentre Technologies generous gift W. Reznikoff) solution
assemble elaborate transposon delivery vector                    containing 40 mM Tris-acetate (pH 7.5), 100 mM potassium glutamate, 0.1 mM
tight regulation replication transposase expression;                 EDTA, 1 mM dithiothreitol, tRNA (0.1 mg/ml). Samples incubated (iii) limit insertion cell achieved based                30 min 37Â°C dialyzed 10 mM Tris-acetate, pH 7.5, plus 1 mM ratio transposome complexes competent cells                    EDTA 0.05-â?®m filters (Millipore, Bedford, Mass.) 1 h. Dialyzed samples
                                                                                mixed electrocompetent E. coli 1:2 ratio (vol/vol) transformed
time transformation.                                                         electroporation. Cultures immediately diluted Luria-Bertani-
   Computational techniques identification potential                 based rich medium   kanamycin incubated 37Â°C 40
drug targets based genomic data reviewed                        min gentle agitation. efficiency electroporation E. coli strains
cently (35, 37, 67, 79). studies, silico analysis               MG1655 DH10B 5 â«» 104 2 â«» 106 kanamycin-resistant colonies successfully combined experimental techniques (4, 23,                      1 â?®g transposon DNA, respectively.
                                                                                   Outgrowth mutagenized population. Half mutagenized population
36). example, Arigoni coauthors used comparative                        immediately frozen stored time zero sample. rest genome analysis identify previously uncharacterized genes                    culture used inoculate BIOFLO 2000 fermentor (New Brunswick Sci- potential broad-spectrum targets emphasizing genes                        entific, Edison, N.J.) containing 950 ml following medium: tryptone, 10   broadly conserved various bacteria, including                  g/liter; yeast extract, 5 g/liter; 50 mM NaCl, 9.5 mM NH4Cl, 0.528 mM MgCl2,
                                                                                0.276 mM K2SO4, 0.01 mM FeSO4, 5 â«» 10â«º4 mM CaCl2, 1.32 mM K2HPO4.
pathogens; (ii) conserved humans; (iii) likely                                                                                 medium supplemented following micronutrients: 3 â«» 10â«º6 mM
encode soluble proteins. essentiality selected genes                 (NH4)6(MoO7)24, 4 â«» 10â«º4 mM H3BO3, 3 â«» 10â«º5 mM CoCl2, 10â«º5 mM CuSO4, assessed directed knockouts E. coli Bacillus                  8 â«» 10â«º5 mM MnCl2, 10â«º5 mM ZnSO4 (68). following vitamins subtilis (4). silico target identification techniques               added (concentrations milligrams liter): biotin, 0.12; riboflavin, 0.8;
focused formal comparative sequence analysis,                     pantothenic acid, 10.8; niacinamide, 12.0; pyridoxine, 2.8; thiamine, 4.0; lipoic
                                                                                acid, 2.0; folic acid, 0.08; p-aminobenzoic acid, 1.37. Kanamycin added
tempting assess conservation overall biological                   10 â?®g/ml. fermentation temperature held 37Â°C, dis-
text various pathogens human host. believe                   solved oxygen held 30 50  saturation, pH held 6.95
comparative analysis pathways biological subsystems                       titration 5  H3PO4). Media growth conditions designed significantly improve ability select potential targets.              minimize number genes required cell survival. Cells grown                                                                                 batch culture 23 population doublings (12 h) cell density 1.4 â«» 109.
   approach identification pri-
                                                                                Genomic DNA isolated used generate genetic footprints.
oritization broad-spectrum antimicrobial targets known                     Detection transposon insertions nested PCR. pairs primers functional roles. use list essential genes inferred                  used consecutively, second pair primers nested  genetic footprinting model microorganism (E. coli)                    Fig. 2A). primer pair contained transposon-specific primer starting point analysis corresponding functional roles               chromosome-specific primer. Chromosome-specific landmark primers 
                                                                                signed ordered set unidirectional primer pairs covering entire E. coli context metabolic pathways microbial pathogens.                    genome using custom software. Pairs separated average 3,500 bp, kind comparative analysis based metabolic recon-                     primers pair separated shortest possible distance
struction genomic data indicates suitable target pathways                  range â«º3 900 bp. Average primer length 27 bp (sequences available target functions pathways,                      request). Transposon-specific primers chosen avoid significant
                                                                                similarity E. coli chromosome, using PrimerSelect software (DNA-
potential range pathogens target. Comparison                                                                                 STAR, , Madison, Wis.). pairs nested, outwardly directed transposon-
microbial pathways individual target proteins                    specific primers  end) used detect transposons inserted human counterparts allows target prioritization. Fi-                    orientations  Fig. 2A). forward primer pair includes external
nally, prospective targets validated directed knockouts                  primer, 5â¬˜-GTTCCGTGGCAAAGCAAAAGTTCAA-3â¬˜, internal model pathogens (Staphylococcus aureus H. influenzae).                    primer, 5â¬˜-GGTCCACCTACAACAAAGCTCTCATCA-3â¬˜. reverse primer
                                                                                pair includes external primer, 5â¬˜-CCGACATTATCGCGAGCCCATTTAT- corresponding proteins cloned representative
                                                                                3â¬˜, internal primer, 5â¬˜-GCAAGACGTTTCCCGTTGAATATGGC-3â¬˜.
pathogens human cDNA libraries, expressed analyzed                         consecutive PCR amplifications  external PCR)  advanced target proteins representa-                   performed following conditions: 95Â°C 1 min; 94Â°C 12 s, 70Â°C tive bacterial sources, human counterparts,                6 min (2 cycles); 94Â°C 12 s, 69Â°C 6 min (2 cycles); 94Â°C 12 s, 68Â°C crystallized, structures determined assist                  6 min (36 cycles); 68Â°C 6 min. Amplification reactions contained 0.3 â?®g                                                                                 template DNA (equivalent 6 â«» 107 E. coli genomes), 0.2 mM concentration drug development.                                                       deoxynucleoside triphosphate, 0.4 â?®M concentration primer,
   illustrate approach using examples biosyn-                  PCR buffer (40 mM Tricine-KOH [pH 9.2], 15 mM potassium acetate, 3.5 mM
thesis adenylate cofactors, NAD, coenzyme (CoA),                     magnesium acetate, bovine serum albumin [3.75 â?®g/ml]), 0.4 â?®l Advan- flavin adenine dinucleotide (FAD), presenting                       tage cDNA Polymerase Mix (Clontech Laboratories, Palo Alto, Calif.) 20 â?®l.
                                                                                second internal PCR performed reaction mix, promising targets development novel broad-spec-
                                                                                DNA templates consisted products PCR diluted 103-fold.
trum antibiotics.                                                               Amplification conditions internal PCR follows: 95Â°C 1 min; 94Â°C
                                                                                12 s, 69Â°C 6 min (2 cycles); 94Â°C 12 s, 68Â°C 6 min (9 cycles); 68Â°C
                                                                                6 min. products internal PCRs (3-â?®l aliquots) size separated
                       MATERIALS METHODS
                                                                                0.65  agarose gels. insert detection analysis procedures 
  Strains. E. coli strains MG1655 (Fâ«º lambdaâ«º ilvG rfb50 rph1) (53) DH10B   formed 96 format.
[Fâ¬˜ mcrA âŒ¬(mrr-hsdRMS-msrBC) â?¾80lacZâŒ¬M15 âŒ¬lacX74 endA1 recA1 deoR                  Image capture analysis performed 1D Image Analysis Software
âŒ¬(ara-leu)7697 araD139 galU galK nupG rpsL] (42) S. aureus strain RN4220    (Eastman Kodak Company, Rochester, N.Y.). Mapping detected Tn5
(55) used work.                                                    insertions using custom software, calculates insert positions
 VOL. 184, 2002                                                                GENETIC FOOTPRINTING COFACTOR BIOSYNTHESIS                                       4557
 genome sequence using addresses internal landmark primers               TABLE 1. Genetic footprinting E. coli genes related size corresponding PCR products. Visualization insert locations           metabolism adenylate cofactors NAD(P), CoA, FAD using custom software integrated ERGO database. mi-
crobial genome database WIT, predecessor ERGO, described                                                                     inserts
                                                                                       Biosynthetic                      ORF size       ORF strain: Conclusionb
previously (71).                                                                                          Gene
                                                                                        subsystem                         (bp)
   Optimization experimental conditions low-noise detection transposon                                                       MG1655 DH10B
insertions. Reaction conditions optimized using small set control genes known essentiality, order detect maximum number inserts,       NAD            nadB                 1,620           9        ND           N
keeping level PCR-introduced noise low.  minimum                         nadA                 1,041          12        ND           N genomic DNA contained representative mix mutant chromo-                            nadC                   891           1         4           N
somes consistently yielded reproducible patterns bands PCR                            ushA                 1,650           6        ND           N
determined. Second, products external corresponding internal PCRs                          pnuC                   717           4        ND           N analyzed agarose gel. comparison used                           nadR                 1,251           6         4           N
guide optimizing PCR parameters: cooling rate, number cycles                            pncA                   657           2        ND           N
external versus internal PCR, rate PCR productsâ€™ dilutions. PCR                            pncB                 1,200           8        ND           N
conditions fine-tuned yield minimum number false products,                             nadD (ybeN)            639           1         4           Ec  internal PCR bands lacking corresponding external PCR product.                            nadE                   825           0         1           E  genetic footprints 4-kb nadD locus generated independently                           nadF (yfiB)            876           0         0           E
using identical template DNA samples different chromosome-specific
nested primer pairs. footprints yielded coherent patterns, consistently       CoA            panD                   378            2        0           N
visualizing 10 transposon inserts area (data shown). Finally, 12 random                    panB                   792            1        3           N
internal PCR bands gel purified sequenced. bands originated                          panE                   909            5        2           N expected chromosomal loci. Comparison calculated insert loca-                         panC                   849            1        5           N
tions sequencing results indicated mapping error introduced gel                         coaA                   948            0        0           E
electrophoresis 4.5  size band.                                               coaBC (dfp)          1,290            0        0           E
   Metabolic reconstruction genomic sequence data. versions ge-                           coaD (kdtB)            477            0        0           E
nomes used work follows: E. coli K-12 MG1655 (18) (GenBank                             coaE (yacE)            618            0        0           E
accession  U00096), P. aeruginosa PAO1 (88) (GenBank accession                                  acpS                   378            0        0           E
AE004091), Bacillus anthracis Ames (http://www.tigr.org/tdb/mdb/mdbinprogress
.html), Mycobacterium tuberculosis H37Rv (24) (GenBank accession  AL123456),        FMN/FAD ribA                          588            0        0           E
H. pylori J99 (3) (GenBank accession  AE001439), S. aureus COL (http://www.tigr             ribD                        1,101            0        0           E
.org/tdb/mdb/mdbinprogress.html/), S. pneumoniae (GenBank accession                         ribB                          651            0        0           E
AE005672), M. genitalium (34) (GenBank accession  L43967), H. influenzae Rd                 ribH                          468            0        0           E
(32) (GenBank accession  L42023), Chlamydia trachomatis (87) (GenBank accession             ribE                          639            0        0           E  AE001273), Homo sapiens (http://www.ncbi.nlm.nih.gov/genome/guide/                     ribF (yaaC)                   939            0        0           E
human/).                                                                                                                                                                              number transposon insertions gene strains MG1655    Comparisons specific biochemical capabilities E. coli, relevant bac-      DH10B detected logarithmic aerobic outgrowth 23 population dou-
terial pathogens, human host based metabolic reconstructions           blings rich medium shown.
performed ERGO database. Metabolic reconstructions ERGO                     b
                                                                                            Assessments gene essentiality, based results genetic footprinting tentative projections known biochemical pathways specific organism       strains MG1655 DH10B. E, essential; N, nonessential; ND, determined.
                                                                                          c completely sequenced annotated genome (described reference 82).               nadD appeared nonessential genetic footprinting experi- projections based presence absence orthologs specific        ments shown essential directed-knockout technique.
genes known, basis studies organisms, involved corresponding pathways. approach produces estimate metabolic
potential given organism  asserted pathways actually expressed specific conditions) direct experimental
data falls short defining actual metabolic fluxes.                               quence, using database size 106 high-cutoff E value 104.    Examples illustrating type analysis given Tables 2 4    resulting E values indication closely bacterial sequences metabolic subsystems (groups pathways) related biosynthesis ade-          related remote human sequence conserved core nylate cofactors NAD(P), CoA, FAD. define pathway series              bacterial group  higher E value  higher divergence .
consecutive transformations bifurcations (82). Merging alterna-            Verification gene essentiality E. coli. direct verification gene
tive pathways (numbered II, , Table 2) combined higher             essentiality E. coli used pKO3-based allelic exchange (58). briefly
hierarchical blocks, ultimately form subsystem. contrast pathways,       illustrated using nadD example. Deletion gene (predicted subsystems formally defined boundaries, assembled             essential) attempted parallel nadR  nonessential gene based conventions field  cofactor biosynthesis described          metabolic subsystem) control. E. coli nadD (12, 63)  references 5, 12, 13), biological expertise interests   ybeN) nadR genes flanking regions PCR amplified using
particular user.                                                                       MG1655 genomic DNA template following primers: 5â¬˜-CAGCTG
   Profile HMMs. comparisons human bacterial sequences                 ATTCGTAAGCTGCCAAGCATC-3â¬˜ 5â¬˜-GGGGTCGACTCACTCACGG using HMMER 2.2 program (30; http://hmmer.wustl.edu/),              TGATAAGGATGGTTGGTGGTGATG-3â¬˜ nadD 5â¬˜-TGGCCTGCCG
multiple-sequence alignments obtained CLUSTAL-W (90). built            ACTGACAATCTC-3â¬˜ 5â¬˜-GCTGGAAAACGCCCTGCTGGAGT-3â¬˜ profile hidden Markov model (HMM) target enzyme, using ortholog           nadR. PCR products cloned gene replacement vector pKO3
sequences pathogens  specified Fig. 5A. HMMs            (58).  650-bp HincII-ClaI fragment nadR replaced 1.7-kb following enzymes built using length protein sequences            Eco57I DNA fragment containing tetracycline resistance cassette nicotinic acid mononucleotide adenylyltransferase (NaMNAT), NAD synthetase             pACYC184 (GenBank accession  X06403). Similarly, 434-bp ApaLIBglII
(NADS), NAD kinase (NADK), pantothenate kinase (PK), phosphopantetheine                fragment nadD excised replaced kanamycin resistance cas-
adenylyltransferase (PPAT), dephospho-CoA kinase (DPCK). Protein                sette pUC4K (GenBank accession  X06404). E. coli strain MG1655 mains roughly corresponding amino acid residues 1 212 213 413          transformed deletion plasmids. Following cointegration, resolution, E. coli CoaBC protein used phosphopantothenoylcysteine             elimination plasmids, Kmr Sucr colonies screened sensitivity
carboxylase (PPCDC) phosphopantothenoylcysteine synthetase (PPCS)                  chloramphenicol (58). Final verification gene replacement HMMs, respectively. Likewise, protein domains approximately corresponding           PCR analysis primers flanking region recombination.
amino acid residues 1 176 177 214 E. coli RibF protein used         case nadR, gene replacement readily achieved: 98  Kmr Sucr build profile HMMs FAD synthase (FADS) flavokinase (FK), respec-             colonies Cms, Kmr Sucr Cms colonies tested PCR
tively. Obtained HMMs run bacterial human se-               contained expected deletion chromosome. case nadD, Kmr
                                                                                                                                                                                                                                                                                  4558
                                                         TABLE 2. Functional reconstruction metabolic pathways NAD/NADP biosynthesisa
                                                                                                                                                       Presence ortholog pathway genome 


                                                                                         Protein
                    NAD(P) biosynthesis                                EC 
                                                                                         example




                                                                                                            E. colib
                                                                                                                        P. aeruginosa
                                                                                                                                        B. anthracis
                                                                                                                                                         M. tuberculosis
                                                                                                                                                                           H. pylori
                                                                                                                                                                                       S. pneumoniae
                                                                                                                                                                                                       S. aureus
                                                                                                                                                                                                                   M. genitalium
                                                                                                                                                                                                                                   H. influenzae
                                                                                                                                                                                                                                                   C. trachomatis
                                                                                                                                                                                                                                                                    H. sapiens
                                                                                                                                                                                                                                                                                 GERDES ET AL.



 novo pathways NaMN                                                                                  Yes          Yes              Yes             Yes                Yes                                                                       Yes
   Tryptophan quinolinate                                                                            â«º            â«º                â«º               â«º                  â«º           â«º               â«º           â«º               â«º               â«º                â«¹
 (II) Aspartate quinolinate
    Aspartate oxidase                                                1.4.3.16         giå…©16130499         nadB         â«¹                â«¹               â«¹                  â«¹           â«º               â«º           â«º               â«º               â«º                â«º
    Quinolinate synthase                                                              giå…©16128718         nadA         â«¹                â«¹               â«¹                  â«¹           â«º               â«º           â«º               â«º               â«º                â«º
 Quinolinate NaMN
    Quinolinate phosphoribosyl transferase                           2.4.2.19         giå…©16128102         nadC         â«¹                â«¹               â«¹                  â«¹           â«º               â«º           â«º               â«º               â«º                â«¹

Salvage: niacin NaMN/NMN                                                                          Yes          Yes              Yes             Yese                        Yes             Yes         Yes                                        Yes
    Nicotinamide NaMN
     Nicotinamide deamidase                                          3.5.1.19         giå…©140602           pncA         â«¹                â«¹               â«¹                  â«º           â«¹               â«¹           â«º               â«º               â«º                â«º
     Nicotinate phosphoribosyl transferase                           2.4.2.11         giå…©16128898         pncB         â«¹                â«¹               â«¹                  â«º           â«¹               â«¹           â«º               â«º               â«º                â«º
  (II) Nicotinamide NMN
     Nicotinamide phosphoribosyl transferase (nadVc)                 2.4.2.12         giå…©13629024         â«º            â«º                â«º               â«º                  â«º           â«º               â«º           â«¹               â«º               â«º                â«¹

Salvage: exogenous NMN NAD                                                                        Yes          Yes                                                                                       Yes                               NMN phosphohydrolase (extracellular) (nadNd)                     3.1.3.5          giå…©1573165          ushA         â«º                â«¹               â«º                  â«º           â«º               â«º           â«º               â«¹               â«º                â«¹
    Pyridine nucleoside transporter                                                   giå…©16273640         pnuC         â«¹                â«¹               â«º                  â«¹           â«¹               â«º           â«º               â«¹               â«º                â«º
    Nicotinamide ribose kinasef                                      2.7.1.22         giå…©16132207         nadR         â«¹                â«º               â´™                  â«º           â«º               â«º           â«º               â´™               â«º                â«º
    NMN adenylyltransferase
         NMN specific (archaea, bacteria)                     2.7.7.1          giå‚¨16132207         nadR         â«º                â«º               â´™                  â«º           â«º               â«º           â«º               â´™               â«º                â«º
       (ii) NaMN/NMN specific (eukarya)                              2.7.7.1/18       giå…©11245478         â«º            â«º                â«º               â«º                  â«º           â«º               â«º           â«º               â«º               â«º                â«¹

Common pathway NAD/NADP                                                                                Yes          Yes              Yes             Yes                Yes         Yes             Yes         Yes             Yes                           Yes
  NaMN NAD
   NaMN adenylyltransferase
       NaMN specific  bacteria)                               2.7.7.18         giå…©1723307          nadD         â«¹                â«¹               â«¹                  â«¹           â«¹               â«¹           â«¹               â«º               â«º                â«º
     (ii) NaMN/NMN specific (eukarya)                                2.7.7.1/18       giå…©11245478         â«º            â«º                â«º               â«º                  â«º           â«º               â«º           â«º               â«º               â«º                â«¹
   NAD synthetase                                                    6.3.5.1          giå…©16129694         nadE         â«¹                â«¹               â«¹                  â«¹           â«¹               â«¹           â«¹               â«º               â«º                â«¹
  NAD NADP
   NAD kinase                                                        2.7.1.23         giå…©8489010          nadF         â«¹                â«¹               â«¹                  â«¹           â«¹               â«¹           â«¹               â«¹               â«º                â«¹
       Subsystems, pathways, individual functional roles (specified Enzyme Classification [EC] numbers) involved adenylate cofactor biosynthesis relevant organisms presented nodes branches (rows) hierarchical tree. Proteins shown representative examples (GenBank ID numbers). presence (â«¹) absence (â«º) orthologous gene specific genome marked column corresponding organism, E. coli, actual gene names given. Alternative pathways subsystem indicated uppercase roman numerals. Nonorthologous genes functional role shown separate rows indicated lowercase roman numerals. Bifunctional (fused) proteins functional domain shown boldface type. â€œYesâ€? indicates particular subsystem asserted given organism presence required genes (enzymatic functions) genome.  ? indicates particular subpathway asserted organism basis genomic data  Functional
roles inferred metabolic context analysis associated specific genes (â€œmissing genesâ€?) indicated question marks.
   b
     Identical patterns pathways similar genes E. coli, Salmonella enterica serovar Typhi, Yersinia pestis subsystems considered.
   c
     Identified Haemophilus ducreyi; present V factor-independent Pasteurellaceae, H. influenzae (62).
   d
     Identified H. influenzae (76); closest homolog E. coli ushA.
   e
     Experimental data suggest pathway functional M. tuberculosis (83).
   f
     corresponding function E. coli H. influenzae catalyzed C-terminal domain multifunctional protein NadR (O. Kurnasov et al., unpublished data).
                                                                                                                                                                                                                                                                                 J. BACTERIOL.
 4559
GENETIC FOOTPRINTING COFACTOR BIOSYNTHESIS




                                                                                                             TABLE 3. Functional reconstruction metabolic pathways CoA biosynthesisa
                                                                                                                                                                                                       Presence ortholog pathway genome 




                                                                                                                                                                                                         M. tuberculosis




                                                                                                                                                                                                                                       S. pneumoniae




                                                                                                                                                                                                                                                                                                   C. trachomatis
                                                                                                                                                                                                                                                                   M. genitalium
                                                                                                                                                                        P. aeruginosa




                                                                                                                                                                                                                                                                                   H. influenzae
                                                                                                                                          Protein




                                                                                                                                                                                        B. anthracis
                                                                        CoA biosynthesis                                 EC 




                                                                                                                                                                                                                                                                                                                    H. sapiens
                                                                                                                                          example




                                                                                                                                                                                                                                                       S. aureus
                                                                                                                                                                                                                           H. pylori
                                                                                                                                                             E. colib
                                                 novo pathway pantothenate                                                                           Yes          Yes             Yes             Yes                Yes                      Yes                                                                                                   Aspartate â?¤-alanine
                                                     Aspartate 1-decarboxylase                                         4.1.1.11        giå…©1786323          panD         â«¹               â«¹               â«¹                  â«¹           â«º               â«¹           â«º               â«º               â«º                â«º
                                                  Ketovalerate pantoate
                                                     3-Methyl-2-oxobutanoate hydroxymethyl transferase                 2.1.2.11        giå…©1786326          panB         â«¹               â«¹               â«¹                  â«¹           â«º               â«¹           â«º               â«º               â«º                â«º
                                                     2-Dehydropantoate 2-reductase
                                                         2-Dehydropantoate 2-reductase                               1.1.1.169       giå…©1100871          panE         â«¹               â«¹               â«¹                  â«º           â«º               â«¹           â«º               â«º               â«º                â«º
                                                       (ii) Ketol-acid reductoisomerase                                1.1.1.86        giå…©146477           ilvC         â«¹               â«¹               â«¹                  â«¹           â«¹               â«¹           â«º               â«¹               â«º                â«º
                                                  â?¤-Alanine, pantoate pantothenate
                                                     Pantoate-â?¤-alanine ligase                                         6.3.2.1         giå…©1786325          panC         â«¹               â«¹               â«¹                  â«¹           â«º               â«¹           â«º               â«º               â«º                â«º
                                                 Pantothenate (vitamin B5) salvage                                                                         Yes          Yes             Yes             Yes                Yes         Yes             Yes                      Yes                           Yes
                                                     Sodium/pantothenate symporter                                                     giå…©455654           panF         â«¹               â«¹               â«¹                  â«¹           â«¹               â«¹           â«º               â«¹               â«º                â«¹
                                                 Common pathway CoA                                                                                     Yes          Yes             Yes             Yes                Yes         Yes             Yes                      Yes                           Yes
                                                    Pantothenate kinase                                                                                                 ?f                                                 ?f
                                                        bacteria                                                2.7.1.33        giå…©1790409          coaA         â«º               â«º               â«¹                  â«º           â«¹               â«º           â«º               â«¹               â«º                â«º
                                                      (ii) Eukarya                                                     2.7.1.33        giå…©6320740c         â«º            â«º               â«¹               â«º                  â«º           â«º               â«¹           â«º               â«º               â«º                â«¹
                                                    Phosphopantothenoylcysteine synthetase                             6.3.2.5         giå…©1790070          coaBe        â´™               â´™               â´™                  â´™           â«¹               â´™           â«º               â´™               â«º                â«¹
                                                    Phosphopantothenoylcysteine decarboxylase                          4.1.1.36        giå…©1790070          coaCe        â´™               â´™               â´™                  â´™           â«¹               â´™           â«º               â´™               â«º                â«¹
                                                    Pantetheine-phosphate adenylyltransferase
                                                        Bacteria                                                     2.7.7.3         giå…©1790065          coaD         â«¹               â«¹               â«¹                  â«¹           â«¹               â«¹           â«º               â«¹               â«º                â«º
                                                      (ii) Eukarya                                                     2.7.7.3         giå…©632171d          â«º            â«º               â«º               â«º                  â«º           â«º               â«º           â«º               â«º               â«º                â´™
                                                    Dephospho-CoA kinase                                               2.7.1.24        giå…©1786292          coaE         â«¹               â«¹               â«¹                  â«¹           â«¹               â«¹           â«¹               â«¹               â«¹                â´™
                                                                                                        Table 2, footnote  details.
                                                   b
                                                     Identical patterns pathways similar genes E. coli, Salmonella enterica serovar Typhi, Yersinia pestis subsystems considered.
                                                   c
                                                     Eukaryotic pantothenate kinase (21), structurally unrelated corresponding E. coli enzyme (CoaA family).
                                                   d
                                                     Eukaryotic pantetheine-phosphate adenylyltransferase distantly related corresponding bacterial enzymes  recognition Psi-Blast) (27); forms fusion protein dephospho-CoA kinase                                                  higher eukaryotes.
                                                   e
                                                     bacteria  S. pneumoniae set), CoaB C-terminal domain, CoaC N-terminal domain bifunctional protein.
                                                   f
                                                     Pantothenate kinase â€œmissing geneâ€? number bacterial pathogens.
VOL. 184, 2002
                                                                                                                                                                                                                                                                                                       4560
                                                                                                                                                                                                                                                                                                      GERDES ET AL.




                                                         TABLE 4. Functional reconstruction metabolic pathways FMN/FAD biosynthesisa
                                                                                                                                                                          Presence ortholog pathway genome 


                                                                                                           Protein
                              FMN/FAD biosynthesis                                         EC           example




                                                                                                                            E. colib
                                                                                                                                           P. aeruginosa
                                                                                                                                                           B. anthracis
                                                                                                                                                                              M. tuberculosis
                                                                                                                                                                                                H. pylori
                                                                                                                                                                                                            S. pneumoniae
                                                                                                                                                                                                                            S. aureus
                                                                                                                                                                                                                                        M. genitalium
                                                                                                                                                                                                                                                        H. influenzae
                                                                                                                                                                                                                                                                        C. trachomatis
                                                                                                                                                                                                                                                                                         H. sapiens



 novo pathways riboflavin                                                                                             Yes             Yes             Yes               Yes                Yes         Yes             Yes                      Yes             Yes               Ribuloso-5-phosphate L-3,4-dihydroxy-2-butanone-4-phosphate
    3,4-Dioxy-2-butanone-4-phosphate synthetase                                           4.1.2.-        giå…©1789420        ribBc           â´™               â´™                 â´™                  â«¹           â´™               â´™           â«º               â«¹               â´™                â«º
 GTP 5-amino-6-ribitylamino-2,4-(1H,3H)-pyrimidinedione
                                                                                                                                       c
    GTP cyclohydrolase II                                                                 3.5.4.25       giå…©16129238       ribA            â´™               â´™                 â´™                  â«¹           â´™               â´™           â«º               â«¹               â´™                â«º
    Pyrimidine deaminase                                                                  3.5.4.26       giå…©1786616        ribDd           â´™               â´™                 â´™                  â´™           â´™               â´™           â´š               â´™               â´™                â«º
    Pyrimidine reductase                                                                  1.1.1.193      giå…©1786616        ribDd           â´™               â´™                 â´™                  â´™           â´™               â´™           â´š               â´™               â´™                â«º
    Pyrimidine phosphatase                                                                3.1.3                            ?               ?               ?                 ?                  ?           ?               ?           â«º               ?               ?                â«º
 L-3,4-Dihydroxy-2-butanone-4-phosphate, 5-amino-6-ribitylamino-2,4-
       (1H,3H)-pyrimidinedione riboflavin
    6,7-Dimethyl-8-ribityl-lumazine synthase                                              2.5.1.9        giå…©16128400       ribH            â«¹               â«¹                 â«¹                  â«¹           â«¹               â«¹           â«º               â«¹               â«¹                â«º
    Riboflavin synthase                                                                   2.5.1.9        giå…©16129620       ribE            â«¹               â«¹                 â«¹                  â«¹           â«¹               â«¹           â«º               â«¹               â«¹                â«º

Riboflavin (vitamin B2) salvage                                                                                                                      Yes                                        Yes             Yes         Yes                                        Yes
    Riboflavin transporter (ypaA)e                                                                       giå…©16079362       â«º               â«º               â«¹                 â«º                  â«º           â«¹               â«¹           ?               â«º               â«º                ?

Common pathway FMN/FAD                                                                                                  Yes             Yes             Yes               Yes                Yes         Yes             Yes         Yes             Yes             Yes              Yes
   Riboflavin kinase                                                                      2.7.1.26       giå…©16128019       ribFf           â´™               â´™                 â´™                  â´™           â´™               â´™           â´™               â´™               â´™                â«¹
   FAD synthetase                                                                         2.7.7.2
       Bacteria                                                                                        giå…©16128019       ribFf           â´™               â´™                 â´™                  â´™           â´™               â´™           â´™               â´™               â´™                â«º
     (ii) Eukarya                                                                                        giå…©6320159g       â«º               â«º               â«º                 â«º                  â«º           â«º               â«º           â«º               â«º               â«º                â«¹
    Table 2, footnote  details.
 b
   Identical patterns pathways similar genes E. coli, Salmonella enterica serovar Typhi, Yersinia pestis subsystems considered.
 c
   RibA RibB form bifunctional (fused) protein bacteria monofunctional separate proteins E. coli H. influenzae.
 d
   RibD bifunctional (fused) protein bacteria.
 e
   Riboflavin transporter originally identified B. subtilis (56).
 f
   RibF bifunctional (fused) protein bacteria.
 g
   Eukaryotic FAD synthase originally identified S. cerevisiae (100) detectable sequence similarity corresponding bacterial enzymes.
                                                                                                                                                                                                                                                                                                      J. BACTERIOL.
 VOL. 184, 2002                                                                GENETIC FOOTPRINTING COFACTOR BIOSYNTHESIS                        4561

Sucr Cms colonies recovered  192 Kmr Sucr colonies screened),              formed E. coli strain DH10B identical experimental
suggesting nadD essential E. coli growth rich medium.                   conditions.
   Verification predicted gene essentiality S. aureus. Allelic exchange vector
pBT2 utilized verification gene essentiality S. aureus (20). nadD
                                                                                          Preliminary gene essentiality conclusions based
(giå…©15927174) pncA (giå…©15927492) S. aureus orthologs PCR amplified            semiautomatic analysis number relative posi-
using primers 5â¬˜-ATTCCTTGTCGCCCGTTATGC-3â¬˜ 5â¬˜-AACGCGCTTC                            tions inserts retained gene selective 
ATTGTATCCT-3â¬˜ nadD 5â¬˜-GTCCGTTAATCCCACAAGCATCA-3â¬˜                               growth 23 population doublings. Failure recover inserts, 5â¬˜-CGCCGACTTTATCTTTTTCAGC-3â¬˜ pncA. Genomic DNA isolated
                                                                                       presence limited number inserts S. aureus strain ATCC 29213 used PCR template. PCR
products cloned plasmid pCR2.1-TOPO (Invitrogen, Carlsbad, Calif.).          end coding sequence, suggested cells carrying trans- 384-bp NheI-AvrII fragment nadD replaced tetracycline resis-           posons gene viable growth 
tance marker (generous gift M. Smeltzer, University Arkansas Med-          ditions.  occur gene constituted ical Sciences, Little Rock), resulting 4.0-kb DNA fragment containing          cold spot transposition insert polar effect inactivated nadD cloned pBT2 (20). plasmid introduced S. aureus RN4220 electroporation. Following cointegration, resolution,
                                                                                       essential downstream gene. validated technology elimination plasmid (20), tetracycline-resistant (Tetr) colonies       combination following controls:   genetic foot-
screened sensitivity chloramphenicol. Tetr Cms colonies        printing mutagenized population prior outgrowth case nadD, pncA successfully inactivated control exper-        (time zero sample) number genes previously estab-
iment. case, 38  Tetr colonies Cms, Tetr
                                                                                       lished essential (Fig. 2B), (ii) verification consistency
Cms colonies tested PCR contained correct pncA deletion chro-
mosome.                                                                                preliminary essentiality assignments metabolic
   S. aureus coaD ortholog (giå…©15926709) flanking regions amplified       biological context gene  , (iii) compar- PCR using primers 5â¬˜-GATTGCCAGTTGTAGGGTTCATA-3â¬˜ 5â¬˜-GC                           ison observed essentiality data reported GTTGGCTTAATCACAGAATA-3â¬˜, cloned pBT2  produce plasmid                          literature, (iv) genetic footprinting presence pMF32), subjected vitro transposon mutagenesis. end artificial transposon constructed (M. Farrell et al., unpublished data)                                                                                        complementing DNA fragment  example, reference
cloning Tet M marker derived Tn916 (38) pMOD-2â¬?MCSâ¬Ž                      27).
(Epicentre Technologies). Plasmid pMF32 mixed 1:1 molar ratio               Global transposon mutagenesis E. coli. Libraries 2 â«»
Tet M-transposon DNA, EZ::TN transposase (Epicentre Technologies)              105 independent insertion mutants generated E. coli
added 0.1-U/â?®l final concentration. mixture incubated 2 h                                                                                        strains MG1655 DH10B using Tn5-based EZ::TNâ¬?KAN-
37Â°C reaction buffer (50 mM Tris-acetate [pH 7.5], 150 mM potassium acetate,
10 mM magnesium acetate, 40 mM spermidine) used transform E.                2â¬ŽTnp transposome (Epicentre Technologies) transposon
coli strain DH10B. Tetr E. coli colonies screened            delivery  utilizes mutant hyperactive form cell PCR, different transposon-containing pMF32 plasmids se-             Tn5 transposase, reported low inser-
lected, including plasmids containing coaD inactivated single transposon      tion site specificity (41, 64). study EZ::TN transposase
insertion middle gene plasmids transposon open
reading frames (ORFs) immediately upstream downstream coaD.                                                                                        sufficiently random yield 1 14 indepen-
plasmids used parallel pBT2-driven allelic exchange S. aureus           dent insertions majority E. coli genes  example,
RN4220  . Tetr Cms (knockout) colonies obtained coaD             Fig. 2). average insertion density experimentally
disruptions, neighboring ORFs (encoding giå…©15926708                      determined insert 250 bp  outgrowth).
giå…©15926710) successfully inactivated.
                                                                                        total number 105 independent insertion mu-
   Preliminary characterization bacterial targets human counter-
parts. Representative bacterial target enzymes human counterparts            tants analyzed 23 cell divisions theoretically corresponds expressed E. coli BL21(DE3) N-terminal fusions tag           insert 46 bp genomic sequence  E. coli
using pProEX-HT3a (Invitrogen). Corresponding DNA fragments                 genome size 4,639 kb). believe difference amplified PCR using bacterial genomic DNA (American Type Culture               slight preferences target sequence recognition
Collection, Manassas, Va.) human brain cDNA (Clontech) primers gen-
erating NcoI BspHI site 5â¬˜ end SalI PstI site 3â¬˜ end.
                                                                                       modified Tn5 transposase actually used DNA fragments purified, digested, cloned NcoI SalI            numerical measure bias. data  PstI) restriction sites vector. resulting constructs verified   sixfold difference observed insertion density DNA sequencing. Recombinant proteins purified homogeneity using              250 bp versus frequency expected completely step procedure consisting chromatography Ni-nitrilotriacetic acid aga-
                                                                                       random insertions  46 bp). insertion density al-
rose (Qiagen) gel filtration (Superdex G-200) described previously (28).
Preliminary enzymatic characterizations performed representative bac-         lowed make essentiality assessments 87  E. coli
terial human enzymes involved biosynthesis NAD (NMN                  ORFs, larger 80 amino acid residues NaMNAT), CoA (PPAT), FAD (FADS) using high-performance liquid                      length.
chromatography analysis reaction products coupled enzymatic                 assess reliability approach, compared 
assays, described reference 27. Enzymatic reactions performed presence 0.1 mM ATP 0.1 mM concentration respective
                                                                                       sults 50 min E. coli chromosome gene
substrates: NMN  NaMN), 4â¬˜-phosphopantetheine, flavin mononucleotide             essentiality data compiled literature Genetic
(FMN). High-performance liquid chromatography analysis performed using             Resource Committee Japan (http://www.shigen.nig.ac.jp
ion-pair chromatography isocratic conditions: 100 mM sodium phosphate            /ecoli/pec/Analyses.jsp). 111 nonessential genes listed
buffer (pH 3.5) 8 mM tetrabutylammoniumbromide methanol (8                                                                                         region chromosome, 98 genes (88 ) NaMNAT, 15  PPAT, 30  FADS), column (50 4.6 mm
[inner diameter]), packed 5 â?®M C18 (Supelco).                                     experimentally determined nonessential (retained 
                                                                                       serts) procedure.
                                                                                          81 known essential genes located 50
                                  RESULTS
                                                                                       min E. coli chromosome, transposon insertions   Genetic footprinting (Fig. 1) systematically applied                          detected 70 genes (86 ) experiment. gene determine genes required logarithmic aerobic growth                            81 analyzed, encoding essential cell division protein FtsK E. coli MG1655 enriched Luria-Bertani medium. Genetic                            (11), contained 10 insertions.  inserts footprinting limited chromosomal region                              clustered C-terminal half coding sequence,
 4562     GERDES ET AL.                                                                                                   J. BACTERIOL.




                                     FIG. 1. General scheme E. coli genetic footprinting procedure.



corresponding amino acid residues 780 1329 (Fig. 2C).            genes sets data good agreement. 13 genes N-terminal domain FtsK required role         lacked transposon insertions outgrowth MG1655,
cell division viability (97). suggests genetic foot-     12 did contain inserts strain DH10B  printing used successfully detect  map)          exception nadE, contained single insert vivo essential domains ORFs, cases essen-          DH10B experiment. seven nonessential genes tial region immediately adjacent translational start.       pathways analyzed strains  10 remaining essential genes single transposon insertion         tained inserts MG1655 DH10B. panD lacked detected outgrowth strains            inserts DH10B, MG1655 experiment (MG1655 DH10B). fact              contained  reflect fact DH10B
genes tolerate transposon inserts certain restricted        experiment transposons inserted possible
loci detrimental effect corresponding gene            orientations monitored, orientations product. Similar phenomena reported ge-             mapped MG1655 experiment.
netic footprinting experiments E. coli (45) H.                Comparison MG1655 DH10B genetic footprints
influenzae (1).                                                        permitted detailed mapping deletions DH10B
   Comparison genetic footprints E. coli                chromosome: âŒ¬(ara-leu)7697 (22) âŒ¬lacX74 (10, 89). 
strains. test reproducibility approach, gen-          letion âŒ¬(ara-leu)7697 covers 25.6-kb region, corre-
erated limited genetic footprint E. coli strain DH10B             sponds area 63.4 89.0 kb MG1655 genome
(covering 650 kb chromosome) compared          includes genes polB fruR (Fig. 2E). corresponding region MG1655. Unambiguous es-               Deletion âŒ¬lacX74 corresponds region 340.3 sentiality data strains obtained 530 genes            369.5 kb (total 29.2 kb) MG1655 sequence 
(excluding deleted DH10B). Identical assessments           cludes genes b0324 b0347 possibly
essentiality produced 487 genes (92 ) group.          mhpB  shown). results genetic footprinting experiments MG1655                 transposon insertions produce polar effects? Surpris- DH10B genes controlling biosynthesis NAD, CoA,              ingly, cases transposon insertions detected  FAD presented Table 1. majority            stream known essential genes, expected  VOL. 184, 2002                                                    GENETIC FOOTPRINTING COFACTOR BIOSYNTHESIS                               4563




   FIG. 2. Detection mapping transposon insertions.   Primer strategy nested PCR. Transposon-specific primers shown gray;
chromosome-specific landmark primers shown black. (B) gel image shows analysis chromosomal loci: aspC (nonessential) lpdA ftsJ (essential) time zero (lanes 1, 3, 5) outgrowth (lanes 2, 4, 6). ORF locations marked relative pair lanes. inserts visible lpdA ftsJ time zero, detected outgrowth. nonessential aspC contains
insertions time points. (C E) Examples genetic footprints. Note scale different panel. length direction gene indicated large horizontal gray arrows. Black diamonds represent transposon inserts. width diamond corresponds mapping error introduced gel electrophoresis. positions landmark PCR primers shown bows crossing genes, arrows genes. (C) Genetic footprinting ftsK locus MG1655. 3â¬˜ half essential gene contains inserts.
(D) Genetic footprinting coaD locus MG1655. transposon insertion immediately upstream essential gene apparently does interfere expression. (E) Mapping âŒ¬(ara-leu)7697 deletion DH10B. genetic footprint corresponding region MG1655 shown comparison.



destroy promoter sequences polar effect              inserts nonessential N-terminal regions protein expression downstream genes. case coaD               tolerated interfere translation 
shown Fig. 2D), argS, frr, rplT, secA,          stream sequences. limits subgenic resolution ge- genes. believe EZ::TNâ¬?KAN-2â¬Ž transpo-                     netic footprinting cases multifunctional proteins son sequence inserted orientation capable initi-            essential domains proximal translational start  shown ating level transcription sufficient cell survival         Fig. 2C).
cases, specific promoter sequence added                  Analysis gene essentiality data context E. coli structure. Analysis transposon sequence Neu-              metabolic pathways. major advantages genetic
ral Network Promoter Prediction program (95; http://www                     footprinting directed knockouts identification es-
.fruitfly.org/seq_tools/promoter.html) reveals multiple putative            sential genes fact footprinting fast highly
E. coli-type promoters oriented outwards directions.                parallel method. high-throughput technique, probably explains polar effects transposon inser-               limitations, example, cross-feeding outgrowth
tions downstream genes rarely observed study.                complex mutant population. efficient way minimize  translational polarity distal domains genes              erroneous conclusions respect essentiality likely significant limiting factor technique.         given gene consider results context multifunctional protein essential C-terminal domain,              corresponding metabolic pathway subsystem. Metabolic
 4564     GERDES ET AL.                                                                                                         J. BACTERIOL.




  FIG. 3. Simplified diagrams, illustrating biochemical transformations directly involved biosynthesis NAD(P)  , CoA (B), FMN/FAD (C). pathways genes shown present E. coli, exceptions marked dashed lines. Recycling
pathways transformations related genes remain unknown  NMN deamidase) included.




context analysis allows reconciliation data genetic          chemically genetically. hand, key
footprinting experiments, literature  available),         genes identified recently, essentiality predicted metabolic reconstruction. tech-              directly confirmed. results genetic footprinting
nique efficiently applied E. coli,     majority known E. coli genes involved best-studied model microbial systems. contradictions                biosynthesis salvage pathways producing NAD(P), CoA, types data encountered certain gene,          FAD summarized Tables 2 4. possible formulate probable assertion           Genetic footprinting E. coli genes involved NAD(P)
inspecting behavior E. coli genes           biosynthesis. behavior majority NAD(P) biosyn-
pathway.                                                                 thetic genes genetic footprinting experiments (Table 1)     biosynthesis adenylate cofactors provides good ex-          consistent previously published data meta-
ample utility approach,   cofactors         bolic reconstruction presented Fig. 3A. essential metabolites types organisms, (ii)            expected, genes novo salvage pathways
corresponding pathways E. coli rich essential genes,           appear nonessential, experiments outgrowth oc- (iii) subsystems thoroughly studied bio-             curred rich media containing niacinamide. Nicotinamide
 VOL. 184, 2002                                             GENETIC FOOTPRINTING COFACTOR BIOSYNTHESIS                       4565


riboside (NmR) probably advanced NAD(P) pre-           (kdtB), previously shown essential (36, 45). cursor transported E. coli.       shown Table 1, genes essential genes common pathway essential,       footprinting study, acpS, produces 
inactivation compensated NAD(P) salvage.          zyme responsible covalent attachment CoA acyl car- consistent observations, notable ex-     rier protein, required fatty acid biosynthesis (33).
ception nadD. Multiple insertions gene ob-            Genetic footprinting E. coli genes involved FMN/FAD
served, suggesting nadD dispensable E. coli growth     biosynthesis. FMN/FAD biosynthetic genes rich media. contradicted genetic data Salmonella       essential genetic footprinting experiments enterica serovar Typhimurium (48), exper-       E. coli strains (Table 1). fact genes iments E. coli MG1655, failed produce directed       novo riboflavin biosynthesis essential presence deletion nadD rich medium, presence           riboflavin (0.8 mg/liter) medium consistent 50 â?®M NAD NMN. hands, nadD                 absence riboflavin transporter E. coli K-12 (6). Ribo-
successfully deleted presence plasmid containing     flavin auxotrophs obtained E. coli using specific
functional human nadD ortholog, pyridine nucleotide adeny-         selection steps facilitate riboflavin transport uncharacter-
lyltransferase 1 (PNAT-1) (giå…©12620200; O. Kurnasov, unpub-        ized mutations significantly higher concentrations lished data).                                                      exogenous riboflavin (6, 8, 9).
   possible explanation contradiction pres-        enzymes common flavin pathway, consecutively
ence functional NadR E. coli (Table 2). nadR gene     producing cofactors, FMN FAD, form bifunc- transcriptional regulator novo biosynthesis        tional protein encoded essential ribF gene. enzy-
niacin salvage genes E. coli (92). Recently NadR shown      matic activities expected indispensable, ge- possess low levels NMN adenylyltransferase activity (74)     netic footprinting data suggest essentiality NmR kinase activity (O. Kurnasov et al., unpublished    C-terminal domain (encoding FK). general limitation
data). suggests NadR play role salvaging        technique respect multifunctional proteins.
exogenous NMN. NMN adenylyltransferase activity                summary, 13 genes encoding 16 enzymes NadR involved recycling intracellular NMN           vitamin/cofactor biosynthetic pathways shown 
directly NAD, bypassing NAD synthase encoded             quired aerobic growth E. coli enriched media (Table
nadE (Fig. 3A).  flux PnuC-NadR sal-           1). genes identified essential genetic
vage pathway unlikely sufficient compensate        footprinting agreement published data theoretical
inactivation nadD nadE, responsible        analysis. contradictory case (nadD) reconciled bulk NAD production E. coli (73).  explanation     directed gene deletion strategy. addition, 12 genes
contradicts apparent essentiality nadE observed      related metabolism NAD(P), CoA, FAD ana-
genetic footprinting experiments, compensatory role      lyzed genetic footprinting nonessential PnuC-NadR bypass imply nonessentiality nadE        (Table 1).  results good agreement nadD (Fig. 3A). present propose          available experimental data metabolic reconstructions single unambiguous interpretation contradiction          corresponding pathways.
tween classical genetic genetic footprinting data        essential genes representing potential broad-spectrum
respect nadD.  point disagree-      antibacterial targets analyzed respect ment NAD(P) biosynthesis genetic footprinting       genomic data available selected bacterial pathogens data types evidence.                                  human host  . analysis allows extrapolation
   Genetic footprinting E. coli genes involved pantothe-     experimental gene essentiality data E. coli nate/CoA biosynthesis. contrast complexity            bacterial pathogens, including S. aureus.
NAD(P) metabolism, CoA biosynthetic pathway topo-              Selected target validation. predicted essentiality logically simple (Fig. 3B). genetic footprinting data   S. aureus nadD ortholog (giå…©15927174) confirmed consistent experimental data theoret-      indirect approach. Deletion nadD attempted parallel
ical considerations (Table 1). enzymatic step com-     S. aureus pncA ortholog (giå…©15927492), presumed mon pathway pantothenate CoA nonredundant           dispensable presence exogenous nicotinate, using
indispensable, phosphorylated intermediates      allelic exchange vector pBT2 (20). âŒ¬nadD variants transported cell. eliminates potential        obtained, extensive screening (2,248 colonies), cross-feeding possibility exogenous CoA salvage      control experiment pncA successfully inactivated transport phosphorylated precursors growth         38  colonies screened. indicates nadD medium. genes pantothenate biosynthetic path-       essential S. aureus growth complex tryptic soy
way nonessential bypassed exogenous pan-         broth (Difco Laboratories, Detroit, Mich.).
tothenate known transporter encoded panF gene            different strategy used verify predicted essen-
(51, 93).                                                          tiality S. aureus coaD ortholog (giå…©15926709). vitro
   coaA gene E. coli, encoding pantothenate kinase,     transposon mutagenesis used disrupt coaD enzyme common step pathway pantothe-        adjacent ORFs. conclusion coaD essentiality
nate CoA, previously characterized essential (86, 94).   drawn based fact coaD disrupted
Genes enzymatic steps CoA biosynthesis        neighboring ORFs (giå…©15926708 giå…©15926710)
(coaBC, coaD, coaE) recently discovered         successfully inactivated Tet M transposon, (39, 65). genes, coaE  yacE) coaD        frequencies 83 5 , respectively.
 4566     GERDES ET AL.                                                                                                          J. BACTERIOL.




 FIG. 4. Selection antibacterial drug targets combination genetic footprinting E. coli comparative analysis reconstructed
metabolic subsystems, pathways, individual genes pathogens humans.



   Selected bacterial targets human counterparts               genetic footprinting identifying novel antibacterial drug tar- overproduced E. coli, purified, characterized.           gets (Fig. 4).
respective adenylyltransferase activities following               Experimental gene essentiality data determined genetic
combinant enzymes directly confirmed vitro:                      footprinting analyzed terms relevant E. coli met-
NaMNATs E. coli, S. aureus, H. pylori (giå…©1786858,              abolic subsystems pathways using ERGO database.
giå…©15924584, giå…©2314504, respectively); isoforms hu-          contextual analysis refines essentiality assessment man PNAT, e., PNAT-1 (giå…©12620200) PNAT-2                          gene addressing following questions. met-
(giå…©11245478); PPATs S. aureus, M. tuberculosis, H. influ-          abolic pathway essential gene associated  Does enzae, H. pylori (giå…©15924115, giå…©560525, giå…©1573650,            pathway yield metabolite essential cell viability? giå…©15612433, respectively); PPAT domain human                 route produce metabolite? 
PPAT/DPCK protein (27); FADS domain B. subtilis                   tabolite salvaged growth media final form?
bifunctional FK/FADS protein (giå…©16078730); human                    advanced precursor  point salvage)
FADS (F. Mseeh, unpublished results).                                    cell acquire environment? kind                                                                          analysis generates hypotheses essentiality non-
                                                                         essentiality known genes pathways. Com-
                          DISCUSSION
                                                                         parison models actual genetic footprinting data
   approach identifying ranking antibacterial drug            data available literature (e.g., http://www
targets based combination genetic footprinting              .shigen.nig.ac.jp/ecoli/pec/Analyses.jsp) allows refinement model (E. coli) comparative genome analysis                initial experimental assessments gene essentiality calls schematically illustrated Fig. 4. major components            experimental examination  case nadD). approach, experimental computational, post-                    consistent data compiled E. coli, metabolic
genomic techniques. Genetic footprinting E. coli allows               reconstruction selected pathways extended panel identification essential genes function growth condi-         representative pathogens. hierarchical overview illustrated
tions high-throughput format. relatively new tech-             Tables 2 4 provides convenient way perform com-
nique multiple potential applications functional genom-           parative cross-genome analysis relevant pathways met-
ics. example, monitoring changes pattern gene           abolic subsystems. Questions addressed step essentiality varying growth conditions genetic              analysis include following. pathways present background, possible assess various aspects cell         pathogens consideration? pathways 
metabolism. allow functions previously uncharac-             taining essential genes conserved nonredundant terized genes established allows functional roles          group? functions selected pathways known genes refined. example study             encoded closely related genes? point reflect published recently (7). consider application             likelihood finding small molecule efficiently
 VOL. 184, 2002                                                     GENETIC FOOTPRINTING COFACTOR BIOSYNTHESIS                         4567




                                                                             FIG. 6. General scheme chemical transformations catalyzed                                                                            adenylyltransferases (ATse) biosynthesis NAD(P),
                                                                           CoA, FAD. enzymesâ€”NaMNAT (encoded E. coli                                                                            nadD), PPAT (gene coaD), FADS (ribF) selected                                                                            promising antibacterial drug targets pathways.



                                                                           bind target protein pathogens spectrum
                                                                           suppressing functional activity. use parameters                                                                            preliminary measures likelihood, P values pair-
                                                                           wise sequence comparisons E values produced                                                                            comparing bacterial sequence profile (HMM) built
                                                                           specific panel pathogens  illustrated Fig. 5A    FIG. 5. Prioritization potential broad-spectrum antibacterial        B). structural functional data, elaborate
drug targets biosynthetic pathways NAD(P), CoA, FAD. criteria shown target enzyme (marked abbrevi-        productive criteria applied, conservation ations x axis).   Range pathogens. number patho-       elements active site, relative substrate preferences,
gens  representative set) containing given target enzyme      affinities range natural synthetic ligands.
 included building corresponding HMM) represented            corresponding human pathways reconstructed filled bars. Organisms containing target enzyme 
fore excluded spectrum indicated inside open bars                                                                             genomic data assess potential effects letter abbreviations). (B) Compact pathogen subsets outliers.      arise inhibition human counterparts antibac-
Negative logarithms E values indicate closely bacterial    terial targets. criterion used selecting antibacte-
sequence related probabilistic consensus corresponding    rial targets absence corresponding function profile HMM (larger values indicate higher similarity). Subsets         corresponding pathway human host  
pathogens target orthologs closely related consensus shown inside dotted boxes. Outliers indicated letter        stance, bacterial cell wall biosynthesis). approach, al-
organism abbreviations. Organisms shown P. aeruginosa (E) (PA),        historically productive, unnecessarily rejects
B. anthracis () (BA), M. tuberculosis (Æ’) (MT), H. pylori (â– ) (HP), S.    promising targets. targets universal biosynthetic path-
pneumoniae (äŠ?) (PN), S. aureus (â½§) (SA), M. genitalium (ã€«) (MG),           ways reconsidered new opportuni-
H. influenzae (Å’) (HI), C. trachomatis (â€š) (CT), E. coli (F). E. coli proteins similar Yersinia pestis Salmo-
                                                                           ties provided comparative genomics parallel chemical
nella enterica serovar Typhi. (C) Human counterparts: distance        synthesis. Certain features revealed level host-patho-
bacterial families. negative logarithms E values human       gen comparative genome analysis useful evaluation
counterpart sequences compared corresponding bacterial              targets. instance, pathway unique HMMs (smaller values indicate higher divergence human            pathogens potentially redundant humans  NAD
zyme corresponding bacterial family). â´±â´±, HMM E values human proteins higher threshold (â¬Ž10,000).              biosynthesis), human functional counterpart                                                                            structurally unrelated bacterial proteins. cases  4568     GERDES ET AL.                                                                                                  J. BACTERIOL.


bacterial orthologs target enzyme human version         graded nicotinamide riboside membrane-bound share sequence similarity, prioritize targets based       periplasmic phosphohydrolases, nadN gene prod-
  lowest P values generated pairwise compar-       uct (76). addition, step niacinamide salvage pathway
isons target protein homologs bacterial pathogen        gram-positive pathogens S. pneumoniae S. au- human functional counterpart (ii) E value         reus constitute possible narrow-spectrum target. derived comparison human protein sequence             organisms lack genes novo NAD biosynthesis profile HMM built corresponding pathogen pro-            PnuC-NadR pathway nicotinamide riboside salvage
teins  Fig. 5C).                                               (Table 2).
   illustrate approach, essential conserved genes           step pathway NaMN NAD NADP, known functions biosynthesis key adenylate        requiring NaMNAT, NADS, NADK, conserved cofactors NAD(P), CoA, FAD investigated.              majority bacterial pathogens (Table 2), representing poten-
biosynthetic pathways fit criteria listed        tially broad-spectrum targets. pathway nonredundant, cofactor utilized multiple enzymes pathogens;      corresponding genes essential E. coli (Table 2).
(ii) bacteria unable import cofactors     NaMNAT NADS present C. trachomatis H.
phosphorylated precursors prior degradation; (iii)       influenzae, excludes pathogens target steps biosynthetic pathways universal        profile. Inhibition NADK cover broadest range nonredundant contain number promising targets.          pathogens, excluding C. trachomatis  Fig. 5A). 
   NAD(P) biosynthesis characterized high level            NADK recently characterized H. sapiens (57),
complexity diversity various organisms (60, 66), includ-      revealing high sequence similarity bacterial
ing versions novo biosynthesis          enzymes  P value 2 ä¡  10â«º25 NADK P. aeruginosa
routes salvage exogenous precursors (Table 2 Fig.         significantly better P values pairwise comparison
3A). absence recognizable genes NAD(P) bio-           bacterial orthologs). C-terminal synthase
synthesis genome C. trachomatis (Table 2) suggests         domain human NADS ortholog (giå…©10433831) reveals obligate intracellular parasite unique transport       lower significant sequence similarity machinery salvage NAD NADP.  C. tra-            bacterial counterparts  best P value 6 ä¡  10â«º13 NADS
chomatis excluded panel pathogens used           M. genitalium). Finally, human counterpart bacte- assess targets NAD biosynthesis.                               rial NaMNAT marginal sequence similarity bac-
   Genes controlling novo NAD biosynthesis aspartate         terial enzymes nadD family  best P value â¬ƒ0.2 salvage niacin E. coli nonessential rich        NaMNAT H. pylori). E values derived comparing
media. conclusion projected P. aeruginosa, B.       human PNAT, NADS, NADK profile HMMs anthracis, possibly M. tuberculosis based metabolic        corresponding bacterial protein families support conclu-
constructions (Table 2). cases controversial.   sions (Fig. 5C). Prioritization potentially broad- spite fact genes required niacinamide        spectrum targets NAD biosynthesis combination salvage (pncA pncB) present genome, M. tuber-         criteria summarized Fig. 5 yields target
culosis reported strictly dependent novo        preference order follows: NaMNAT better NADS
NAD biosynthesis (83). pncA expressed M. tubercu-        better NADK.
losis (81, 102), interpretation pncB ortholog        NaMNAT activity initially characterized E. coli (26),
functionally inactive M. tuberculosis, labora-     chromosomal locus mapped Salmonella (48).
tory conditions.                                                      identity structural gene remained 
   Theoretically, bacterial novo NAD biosynthesis         known recently. identified gene based partate attractive target pathway, absent       clustering chromosome nadE pncB gene 
humans, novo biosynthesis occurs step ox-         thologs microbial genomes (12). gene idative degradation tryptophan (66).           independently identified E. coli Mehl coworkers (63).
set bacterial pathogens, H. pylori expected       cloned expressed nadD E. coli useful targets pathway, lacks niacin salvage        cloned expressed orthologs gram-positive (S. au-
genes (Table 2). step conversion aspartate             reus) gram-negative (H. pylori) pathogens (12), quinolinate make excellent target pathway anti-         purified NadD proteins. Analysis substrate
infective agents specific H. pylori (Table 2 Fig. 3A).      specificity purified recombinant proteins revealed strong
systematic analysis essential genes conserved exclusively      preferences bacterial enzymes NaMN H. pylori (23) did recognize potential pathway    NMN  â¬Ž17,000-fold case S. aureus NaMNAT). target drug development, did          bias consistent major flux NAD biosynthesis
account metabolic context organism.                      bacteria going nicotinic acid mononucleotide
   PnuC-NadR pathway nicotinamide riboside salvage            (NaMN) NaAD. H. influenzae provides example narrow spec-             isoforms NadD identified trum target. complete pathway present limited       human genome (giå…©12620200, giå…©11245478, giå…©14029540).
number bacteria, sole route NAD biosyn-         cloned, purified, characterized forms
thesis H. influenzae. H. influenzae requires called V fac-     designated PNAT-1 PNAT-2, tors growth (25, 76), simplest nicotinamide      perform adenylyltransferase reaction equally efficiently
riboside. acceptable V factors, NADP, NAD,             pyridine nucleotides NMN NaMN (O. Kurnasov
NMN  present growth medium), gradually              et al., unpublished data). Human PNAT-2 indepen-
 VOL. 184, 2002                                                GENETIC FOOTPRINTING COFACTOR BIOSYNTHESIS                        4569


dently identified characterized groups (31,          tholog monofunctional PPCDC. Monofunctional
80). observed dual specificity human PNATs consis-          PPCSs S. pneumoniae B. anthracis reveal high
tent previous experimental data (61) recon-         sequence similarity  quite divergent
struction putative human NAD biosynthetic pathway              PPCS domain bifunctional PPCDC/PPCS pro- genomic data (Table 2).                                          teins. contrast bacterial orthologs, produce    difference substrate preferences human              low reliable similarity score compared human
PNATs bacterial NaMNATs additional incentive               monofunctional PPCS (3 ä¡  10â«º23 H. sapiens B.
pursuing NadD selective, relatively broad-spectrum           anthracis). enzyme common pathway, DPCK, antibacterial target. dimensional structures             ubiquitous pathogens set.
NaMNATs E. coli (101) B. subtilis (70)                enzymes human CoA biosynthesis solved association NaMN. Comparison struc-           recently identified characterized (27). 
tures structure human PNAT-2 (103) reveals sig-           PPCDC DPCK, relatively similar bacterial
nificant differences organization active sites,       counterparts (Fig. 5C). human monofunctional PPCS facilitate identification selective antibacterial      distant PPCS domains bacterial bifunctional
inhibitor.                                                            PPCDC/PPCS proteins, closely related    Similar comparative analysis CoA FMN/FAD                bacterial monofunctional PPCDCs. PPAT domain biosynthetic pathways humans bacteria produced addi-           human bifunctional PPAT/DPCK protein reveals signifi-
tional broad-spectrum antibacterial targets (Fig. 5).          sequence similarity bacterial counterpart, novo pathway CoA biosynthesis present bacterial        likely quite dissimilar overall structure. PPAT
pathogens absent humans (Table 3), corre-              probably represents attractive target common
sponding enzymes attractive targets          CoA biosynthetic pathway number reasons:    universal presence pantothenate symporter orthologs.           stitutes target broad range pathogens (Fig. 5A), (ii) pathogens lack novo pantothenate biosynthetic            bacterial orthologs enzyme closely related genes (Table 3) depend solely salvage pantothenate (S.          consensus  outliers; Fig. 5B), (iii) human PPAT pneumoniae H. influenzae) dephospho-CoA (M. geni-              dissimilar bacterial HMM profile (Fig. 5C).
talium C. trachomatis). Bacterial pantothenate symporters         PPAT E. coli (encoded coaD, previously kdtB) (panF family) share high sequence similarity human             previously described, dimensional structure protein implicated vitamin transport (96). panF              solved (39, 50).
thologs present genomes M. genitalium C.                majority bacteria  exception M. geni-
trachomatis. Specific transporters allowing salvage host        talium) considered conserved novo riboflavin
phospho-CoA intracellular pathogens              biosynthetic pathway, present humans (Table 4
represent narrow spectrum targets) unknown.                 Fig. 3C).  genes novo path-
   enzymatic steps common pathway CoA              way essential E. coli (Table 4). observations biosynthesis pantothenate encoded essential genes         brought attention gene products potential E. coli (Table 3). enzymes conserved        antibacterial drug targets (17, 29, 98).  direct exper-
broad range bacterial pathogens. enzyme           imental analysis riboflavin transport salvage pathway, PK, encoded E. coli coaA (86) belongs             pathogens necessary order define useful structural family different recently identified      targets  B. subtilis known effectively salvage exog-
eukaryotic PKs (21). makes coaA-related PKs attrac-           enous riboflavin, bypassing requirement novo
tive target relatively narrow subset list patho-      pathway (19). Orthologs riboflavin transporters,
gens, including H. influenzae, M. tuberculosis, S. pneu-          gene ypaA, recently identified B. subtilis (56) present moniae. S. aureus  staphylococci                 gram-positive pathogens, including B. anthracis, S. au-
enterococci) B. anthracis lack coaA orthologs,           reus, S. pneumoniae, functionality enzymatic function likely performed remote              directly confirmed. Additional structurally dissimilar ri-
thologs eukaryotic PK  trå…©Q99SC8 S. aureus).        boflavin transporters likely exist pathogens. known forms PK identified             example, riboflavin transport occur M. genitalium, sequence similarity analysis P. aeruginosa, H. pylori,       novo riboflavin biosynthesis pathway asserted pathogens included set, suggests       organism (Table 4).  ypaA orthologs existence uncharacterized form enzyme.        available mycoplasma ureaplasma ge-
   remaining enzymes pathway represent poten-         nomes.
tial antibacterial drug targets relatively broad spectrum (Ta-        common pathway FMN/FAD biosynthesis repre-
ble 3). bacteria, enzymatic activities, PPCS          sented bacteria bifunctional enzyme catalyzes
PPCDC, located C-terminal N-terminal               consecutive reactions. reaction formation domains bifunctional (fused) protein (gene coaBC, previ-         FMN, catalyzed FK domain (C terminus). second
ously dfp E. coli). exception list pathogens S.   reaction conversion FMN FAD FADS domain
pneumoniae  streptococci enterococci)            (N terminus). enzymes represent antibacterial targets
containing separate ORFs, coaB coaC, operon            broad range (Fig. 5A). HMM E values  reversed order relative fusion proteins).         group pathogens high (Fig. 5B), indicating
ingly, B. anthracis  Bacillus cereus) contains      targets divergent.  FADS
bifunctional PPCDC/PPCS monofunctional PPCS                  parameter improved removing outliers,
 4570       GERDES ET AL.                                                                                                                                  J. BACTERIOL.

 H. pylori  source divergent pro-                               quired growth survival Haemophilus influenzae. Proc. Natl. Acad.
                                                                                             Sci. USA 99:966â€“971.
teins sample group pathogens) M. genitalium                           3.   Alm, R. , L. S. L. Ling, D. T. Moir, B. L. King, E. D. Brown, P. C. Doig,
(Fig. 5B).                                                                                   D. R. Smith, B. Noonan, B. C. Guild, B. L. deJonge, G. Carmel, P. J.
   contrast known bacteria, eukaryotic FK                             Tummino,  Caruso, M. Uria-Nickelsen, D. M. Mills, C. Ives, R. Gibson,
                                                                                             D. Merberg, S. D. Mills, Q. Jiang, D. E. Taylor, G. F. Vovis, T. J. Trost.
FADS identified S. cerevisiae (78, 100) monofunctional                                1999. Genomic-sequence comparison unrelated isolates hu-
proteins. overexpressed, purified, characterized                                 man gastric pathogen Helicobacter pylori. Nature 397:176â€“180. human enzymes common FMN/FAD biosynthetic                                   4.   Arigoni, F., F. Talabot, M. Peitsch, M. D. Edgerton, E. Meldrum, E. Allet,
                                                                                             R. Fish, T. Jamotte, M. L. Curchod, H. Loferer. 1998. genome-based
pathway (F. Mseeh, unpublished data). Sequence comparison                                    approach identification essential bacterial genes. Nat. Biotechnol. human FK FADS profile HMMs clearly indi-                                     16:851â€“856.
cates FADS potentially selective target (Fig.                            5.   Bacher, , S. Eberhardt, W. Eisenreich, M. Fischer, S. Herz, B. Illarionov,
                                                                                             K. Kis, G. Richter. 2001. Biosynthesis riboflavin. Vitam. Horm.
5C). agreement  reliable P values produced                               61:2â€“49. pairwise comparisons human FADS bac-                              6.   Bacher, , S. Eberhardt, G. Richter. 1996. Biosynthesis riboflavin,
terial counterparts, human FK sequence similar-                                p. 657â€“664. F. C. Neidhardt et al. (ed.), Escherichia coli Salmonella:
                                                                                             cellular molecular biology. ASM Press, Washington, D.C.
ity bacterial FK domains higher similarity                             7.   Badarinarayana, V., P. W. Estep, J. Shendure, J. Edwards, S. Tavazoie, F. bacterial FK domains  example,                                   Lam, G. M. Church. 2001. Selection analyses insertional mutants
                                                                                             using subgenic-resolution arrays. Nat. Biotechnol. 19:1060â€“1065.
M. tuberculosis FK domain gives P value 10â«º9 human
                                                                                        8.   Bandrin, S. V., M. Y. Beburov, P. M. Rabinovich,   Stepanov. 1979.
FK P value 4 ä¡  10â«º6 H. pylori FK domain).                                  Riboflavin auxotrophs Escherichia coli. Genetika 15:2063â€“2065.  Rus-
   conclusion, genetic footprinting E. coli combination                             sian.)
                                                                                        9.   Bandrin, S. V., P. M. Rabinovich,   Stepanov. 1983. 3 linkage groups comparative genome analysis reconstructed metabolic                                  genes riboflavin biosynthesis Escherichia coli. Genetika 19:1419â€“
subsystems pathways allowed identify number                                  1425.  Russian.) antibacterial targets involved biosynthesis ad-                       10.   Beckwith, J. R., E. R. Signer. 1966. Transposition Lac region                                                                                              Escherichia coli.  Inversion Lac operon transduction Lac enylate cofactors NAD(P), CoA, FAD.                                       â?¾80. J. Mol. Biol. 19:254â€“265.
attractive targets pathways adenylyltrans-                        11.   Begg, K. J., S. J. Dewar, W. D. Donachie. 1995. new Escherichia coli
ferases: NaMNAT, PPAT, FADS (Fig. 6).                                       cell-division gene, ftsk. J. Bacteriol. 177:6211â€“6222.
                                                                                       12.   Begley, T. P., C. Kinsland, R.  Mehl,  Osterman, P. Dorrestein.
targets (NaMNAT PPAT) validated direct-                                     2001. biosynthesis nicotinamide adenine dinucleotides bacteria.
ed-knockout strategy S. aureus. orthologs target                              Vitam. Horm. 61:103â€“119.
enzymes representative pathogens, human                          13.   Begley, T. P., C. Kinsland, E. Strauss. 2001. biosynthesis                                                                                              coenzyme bacteria. Vitam. Horm. 61:158â€“171.
counterparts, overproduced, purified, characterized                           14.   Benton, B. L., J. Ving, F. Malouin, P. K. Martin, M. B. Schmid, D. Sun. direct vitro assays. Comparative analysis adenylate                                 March 2000. Methods screening compounds active Staphylococcus
cofactor biosynthesis provides illustration general ap-                              aureus target genes. U.S. patent 6,037,123.
                                                                                       15.   Benton, B. L., J. Ving, F. Malouin, P. K. Martin, M. B. Schmid, D. Sun.
proach extended functional subsystems                                2001. Methods screening compounds active Staphylococcus
reveal novel antibacterial targets.                                                          aureus target genes. U.S. patent 6,228,588.
                                                                                       16.   Bernal, , U. Ear, N. Kyrpides. 2001. Genomes OnLine Database
                                                                                             (GOLD): monitor genome projects world-wide. Nucleic Acids Res.
                                ADDENDUM                                                     29:126â€“127.
                                                                                       17.   Black, M. T., L. K. Shilling, R. K. Stodola, R. L. Warren,  L. Kosmatka,
   manuscript reviewed, genome-wide                                    R. O. Nicholas, L. M. Palmer, M.  Lonetto, J. C. Fedon, J. E. Hodgson,
                                                                                             D. J. C. Knowles. June 2001. RibB. U.S. patent 6,252,044.
analysis essential genes H. influenzae published (2).                        18.   Blattner, F. R., G. Plunkett, C.  Bloch, N. T. Perna, V. Burland, M. Riley,
Comparing essential genes divergent organisms use-                                J. ColladoVides, J. D. Glasner, C. K. Rode, G. F. Mayhew, J. Gregor, N. W.
ful  defining common essential pathways life                                 Davis, H.  Kirkpatrick, M.  Goeden, D. J. Rose, B. Mau, Y. Shao.
                                                                                             1997. complete genome sequence Escherichia coli K-12. Science potential targets development antimicrobial thera-                                277:1453â€“1462.
peuticsâ€? (2). genome-scale list essential nonessen-                         19.   Bresler, S. E., E.  Glazunov, D.  Perumov. 1972. Study tial genes E. coli currently preparation.                                           operon riboflavin biosynthesis Bacillus subtilis. IV. Regulation                                                                                              synthesis riboflavin synthetase. Investigation riboflavin transport
                                                                                             cell membrane. Genetika (USSR) 8:109â€“117.
                          ACKNOWLEDGMENTS                                              20.   BruÂ¨ckner, R. 1997. Gene replacement Staphylococcus carnosus                                                                                              Staphylococcus xylosus. FEMS Microbiol. Lett. 151:1â€“8.
   grateful William Reznikoff Igor Goryshin (University                  21.   Calder, R. B., R. S. B. Williams, G. Ramaswamy, C. O. Rock, E. Campbell, Wisconsin, Madison); Jerry Jendrisak Les Hoffman (Epicentre                           S. E. Unkles, J. R. Kinghorn, S. Jackowski. 1999. Cloning char-
Technologies); Tadhg Begley (Cornell University, Ithaca, N.Y.); Zol-                         acterization eukaryotic pantothenate kinase gene (panK) Aspergil-
tan Oltvai (Northwestern University, Chicago, Ill.); Henry Burd,                         lus nidulans. J. Biol. Chem. 274:2014â€“2020.
                                                                                       22.   Casadaban, M. J., S. N. Cohen. 1980. Analysis gene control signals
Niels Larsen, Gregory Kogan, Yuri Kuniver, Yuri Grechkin, Rob-
                                                                                             DNA fusion cloning Escherichia coli. J. Mol. Biol. 138:179â€“207.
ert Haselkorn (Integrated Genomics) valuable discussions, help,                    23.   Chalker,  F., H. W. Minehart, N. J. Hughes, K. K. Koretke, M.  Lonetto, support project. thank George Church (Har-                            K. K. Brinkman, P. V. Warren,  Lupas, M. J. Stanhope, J. R. Brown, vard Medical School, Boston, Mass.) gift pKO3, Mark                               P. S. Hoffman. 2001. Systematic identification selective essential genes Smeltzer (University Arkansas Medical Sciences) gift                       Helicobacter pylori genome prioritization allelic replacement mu-
pCRII::tet RN4220, Reinhold Bru    Â¨ckner (UniversitaÂ¨t Tu
                                                             Â¨bingen,                        tagenesis. J. Bacteriol. 183:1259â€“1268.
TuÂ¨bingen, Germany) pBT2, Don Clewell (University Mich-                     24.   Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V.
igan, Ann Arbor) plasmid pAM120 containing Tn916.                                    Gordon, K. Eiglmeier, S. Gas, C. E. Barry, F. Tekaia, K. Badcock, D.
                                                                                             Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T.
                                                                                             Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornby, K. Jagels,  Krogh,
                                 REFERENCES                                                  J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M.  Quail, M. 
  1. Akerley, B. J., E. J. Rubin,  Camilli, D. J. Lampe, H. M. Robertson,              Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S.
     J. J. Mekalanos. 1998. Systematic identification essential genes vitro         Squares, J. E. Sulston, K. Taylor, S. Whitehead, B. G. Barrell. 1998.
     mariner mutagenesis. Proc. Natl. Acad. Sci. USA 95:8927â€“8932.                           Deciphering biology Mycobacterium tuberculosis complete
  2. Akerley, B. J., E. J. Rubin, V. L. Novick, K. Amaya, N. Judson, J. J.               genome sequence. Nature 393:537â€“544.
     Mekalanos. 2002. genome-scale analysis identification genes           25.   Cynamon, M. H., T. B. Sorg,  Patapow. 1988. Utilization 
 VOL. 184, 2002                                                                GENETIC FOOTPRINTING COFACTOR BIOSYNTHESIS                                       4571

      tabolism NAD Haemophilus parainfluenzae. J. Gen. Microbiol 134:            49. Hutchison, C. , S. N. Peterson, S. R. Gill, R. T. Cline, O. White, C. M.
      2789â€“2799.                                                                           Fraser, H. O. Smith, J. C. Venter. 1999. Global transposon mutagenesis
26.   Dahmen, W., B. Webb, J. Preiss. 1967. deamido-diphosphopyri-                 minimal mycoplasma genome. Science 286:2165â€“2169.
      dine nucleotide diphosphopyridine nucleotide pyrophosphorylases           50. Izard, T.,  Geerlof. 1999. crystal structure novel bacterial
      Escherichia coli yeast. Arch. Biochem. Biophys. 120:440â€“450.                     adenylyltransferase reveals half sites reactivity. EMBO J. 18:2021â€“2030.
27.   Daugherty, M., B. Polanuyer, M. Farrell,  Lykidis, V. CreÂ´cy-Lagard,        51. Jackowski, S., J. H. Alix. 1990. Cloning, sequence, expression        Osterman. 2002. Complete reconstitution human coenzyme               pantothenate permease (panF) gene Escherichia coli. J. Bacteriol.
      biosynthetic pathway comparative genomics. J. Biol. Chem. 277:21431â€“             172:3842â€“3848.
      21439.                                                                           52. Jenks, P. J., C. Chevalier, C. Ecobichon,  Labigne. 2001. Identifica-
28.   Daugherty, M., V. Vonstein, R. Overbeek,  Osterman. 2001. Archaeal             tion nonessential Helicobacter pylori genes using random mutagenesis
      shikimate kinase, new member GHMP-kinase family. J. Bacteriol.              loop amplification. Res. Microbiol. 152:725â€“734.
      183:292â€“300.                                                                     53. Jensen, K. F. 1993. Escherichia coli K-12 wild types W3110 29.   Debouck, C., J. C. Fedon, D. D. Jaworski, J. Mooney, L. M. Palmer, C. M.             MG1655 rph frameshift mutation leads pyrimidine starvation
      Traini, M. Wang, R. L. Warren, Y. Y. Zhong. December 2001. RibH.                 low pyrE expression levels. J. Bacteriol. 175:3401â€“3407.
      U.S. patent 6,326,462.                                                           54. Judson, N., J. J. Mekalanos. 2000. Transposon-based approaches 30.   Eddy, S. R. 1998. Profile hidden Markov models. Bioinformatics 14:755â€“               identify essential bacterial genes. Trends Microbiol. 8:521â€“526.
      763.                                                                             55. Kreiswirth, B. N., S. Lofdahl, M. J. Betley, M. Oâ€™Reilly, P. M. Schlievert,
31.   Emanuelli, M., F. Carnevali, F. Saccucci, F. Pierella,  Amici, N. Raffaelli,       M. S. Bergdoll, R. P. Novick. 1983. toxic shock syndrome exotoxin
      G. Magni. 2000. Human NMN adenylyltransferase: molecular cloning,                structural gene detectably transmitted prophage. Nature 305:
      chromosomal localization, tissue mRNA levels, bacterial expression,              709â€“712.
      enzymatic properties. J. Biol. Chem. 276:406â€“412.                                56. Kreneva, R. , M. S. Gelâ€™fand,   Mironov, Y.  Yomantas, Y.  Kozlov,
32.   Fleischmann, R. D., M. D. Adams, O. White, R.  Clayton, E. F. Kirkness,             S. Mironov, D.  Perumov. 2000. Inactivation ypaA gene        R. Kerlavage, C. J. Bult, J. F. Tomb, B.  Dougherty, J. M. Merrick, K.          Bacillus subtilis; analysis resulting phenotypic expression. Russ.
      McKenney, G. Sutton, W. Fitzhugh, C. Fields, J. D. Gocayne, J. Scott, R.             J. Genet. 36:972â€“974.
      Shirley, L.  Liu,  Glodek, J. M. Kelley, J. F. Weidman, C.  Phillips, T.   57. Lerner, F., M. Niere,  Ludwig, M. Ziegler. 2001. Structural       Spriggs, E. Hedblom, M. D. Cotton, T. R. Utterback, M. C. Hanna, D. T.               functional characterization human NAD kinase. Biochem. Biophys. Res.
      Nguyen, D. M. Saudek, R. C. Brandon, L. D. Fine, J. L. Fritchman, J. L.              Commun. 288:69â€“74.
      Fuhrmann, N. S. M. Geoghagen, C. L. Gnehm, L.  McDonald, K. V.                 58. Link,  J., D. Phillips, G. M. Church. 1997. Methods generating
      Small, C. M. Fraser, H. O. Smith, J. C. Venter. 1995. genome               precise deletions insertions genome wild-type Escherichia coli:
      random sequencing assembly Haemophilus influenzae Rd. Science                 application open reading frame characterization. J. Bacteriol. 179:6228â€“
      269:496â€“512.                                                                         6237.
33.   Flugel, R. S., Y. Hwangbo, R. H. Lambalot, J. E. Cronan, C. T. Walsh.        59. Loferer, H.,  Jacobi,  Posch, C. Gauss, S. Meier-Ewert, B. Seiz-
      2000. Holo-(acyl carrier protein) synthase phosphopantetheinyl trans-            inger. 2000. Integrated bacterial genomics discovery novel anti-
      fer Escherichia coli. J. Biol. Chem. 275:959â€“968.                                 microbials. Drug Discov. Today 5:107â€“114.
34.   Fraser, C. M., J. D. Gocayne, O. White, M. D. Adams, R.  Clayton, R. D.        60. Magni, G.,  Amici, M. Emanuelli, N. Raffaelli, S. Ruggieri. 1999.
      Fleischmann, C. J. Bult,  R. Kerlavage, G. Sutton, J. M. Kelley, J. L.             Enzymology NADâ«¹ synthesis. Adv. Enzymol. Relat. Areas Mol. Biol.
      Fritchman, J. F. Weidman, K. V. Small, M. Sandusky, J. Fuhrmann, D.                  73:135â€“182.
      Nguyen, T. R. Utterback, D. M. Saudek, C.  Phillips, J. M. Merrick, J. F.
                                                                                       61. Magni, G., M. Emanuelli,  Amici, N. Raffaelli, S. Ruggieri. 1997.
      Tomb, B.  Dougherty, K. F. Bott, P. C. Hu, T. S. Lucier, S. N. Peterson,
                                                                                           Purification human nicotinamide-mononucleotide adenylyltransferase.
      H. O. Smith, C.  Hutchison, J. C. Venter. 1995. minimal gene
                                                                                           Methods Enzymol. 280:241â€“247.
      complement Mycoplasma genitalium. Science 270:397â€“403.
                                                                                       62. Martin, P. R., R. J. Shea, M. H. Mulks. 2001. Identification 35.   Freiberg, C. 2001. Novel computational methods anti-microbial target
                                                                                           plasmid-encoded gene Haemophilus ducreyi confers NAD 
      identification. Drug Discov. Today 6:S72â€“S80.
                                                                                           dependence. J. Bacteriol. 183:1168â€“1174.
36.   Freiberg, C., B. Wieland, F. Spaltmann, K. Ehlert, H. Brotz, H. La-
                                                                                       63. Mehl, R. , C. Kinsland, T. P. Begley. 2000. Identification       bischinski. 2001. Identification novel essential Escherichia coli genes
                                                                                           Escherichia coli nicotinic acid mononucleotide adenylyltransferase gene. J.
      conserved pathogenic bacteria. J. Mol. Microbiol. Biotechnol.
                                                                                           Bacteriol. 182:4372â€“4374.
      3:483â€“489.
37.   Galperin, M. Y., E. V. Koonin. 1999. Searching drug targets           64. Meis, R. 2000. EZ::TN transposon insertions target DNA vitro       microbial genomes. Curr. Opin. Biotechnol. 10:571â€“578.                               highly random. Epicentre Forum 7:5. [Online.] http://www.epicentre.com/
38.   Gawron-Burke, C., D. B. Clewell. 1984. Regeneration insertionally             forum.asp.
      inactivated streptococcal DNA fragments excision transposon             65. Mishra, P. K., P. K. Park, D. G. Drueckhammer. 2001. Identification
      Tn916 Escherichia coli: strategy targeting cloning genes          yacE (coaE) structural gene dephosphocoenzyme kinase       gram-positive bacteria. J. Bacteriol. 159:214â€“221.                                   Escherichia coli K-12. J. Bacteriol. 183:2774â€“2778.
39.   Geerlof, ,  Lewendon, W. V. Shaw. 1999. Purification charac-         66. Moat,  G., J. W. Foster. 1987. Biosynthesis salvage pathways       terization phosphopantetheine adenylyltransferase Escherichia coli.          pyridine nucleotides, p. 1â€“20. D. Dolphin O. Avramovich (ed.),
      J. Biol. Chem. 274:27105â€“27111.                                                      Pyridine nucleotide coenzymes, B. John Wiley & Sons, New York,
40.   Goryshin,  Y., J. Jendrisak, L. M. Hoffman, R. Meis, W. S. Reznikoff.          N.Y.
      2000. Insertional transposon mutagenesis electroporation released          67. Moir, D. T., K. J. Shaw, R. S. Hare, G. F. Vovis. 1999. Genomics       Tn5 transposition complexes. Nat. Biotechnol. 18:97â€“100.                             antimicrobial drug discovery. Antimicrob. Agents Chemother. 43:439â€“446.
41.   Goryshin,  Y., J.  Miller, Y. V. Kil, V.  Lanzov, W. S. Reznikoff.     68. Neidhardt, F. C., P. L. Bloch, D. F. Smith. 1974. Culture medium       1998. Tn5/IS50 target recognition. Proc. Natl. Acad. Sci. USA 95:10716â€“              enterobacteria. J. Bacteriol. 119:736â€“747.
      10721.                                                                           69. Nilsen, T. W. June 2001. Method identifying essential functional
42.   Grant, S. G. N., J. Jessee, F. R. Bloom, D. Hanahan. 1990. Differential          genes. U.S. patent 6,248,525.
      plasmid rescue transgenic mouse DNAs Escherichia coli methy-           70. Olland,  M., K. W. Underwood, R. M. Czerwinski, M. C. Lo,  Aula-
      lation-restriction mutants. Proc. Natl. Acad. Sci. USA 87:4645â€“4649.                 baugh, J. Bard, M. L. Stahl, W. S. Somers, F. X. Sullivan, R. Chopra.
43.   Hamer, L., T. M. DeZwaan, M. V. Montenegro-Chamorro, S.  Frank,                2002. Identification, characterization, crystal structure Bacillus sub-
      J. E. Hamer. 2001. Recent advances large-scale transposon mutagenesis.            tilis nicotinic acid mononucleotide adenylyltransferase. J. Biol. Chem. 277:
      Curr. Opin. Chem. Biol. 5:67â€“73.                                                     3698â€“3707.
44.   Hancock, R. E. W., D. Knowles. 1998. approaching end           71. Overbeek, R., N. Larsen, G. D. Pusch, M. Dâ€™Souza, E. Selkov, Jr., N.
      antibiotic era? Curr. Opin. Microbiol. 1:493â€“494.                                Kyrpides, M. Fonstein, N. Maltsev, E. Selkov. 2000. WIT: integrated
45.   Hare, R. S., S. S. Walker, T. E. Dorman, J. R. Greene, L. M. Guzman, T. J.           high-throughput genome sequence analysis metabolic 
      Kenney, M. C. Sulavik, K. Baradaran, C. Houseweart, H. Y. Yu,  Foldes,             construction. Nucleic Acids Res. 28:123â€“125.
       Motzer, M. Walbridge, G. H. Shimer, K. J. Shaw. 2001. Genetic             72. Palmer, L. M., J. M. Pratt, M. Rosenberg. October 2000. Method       footprinting bacteria. J. Bacteriol. 183:1694â€“1706.                               determining gene essentiality pathogen. U.S. patent 6,139,817.
46.   Heinemann, J.  1999. antibiotics cause antibiotic resistance. Drug         73. Penfound, T., J. W. Foster. 1996. Biosynthesis recycling NAD,
      Discov. Today 4:72â€“79.                                                               p. 721â€“730. F. C. Neidhardt et al. (ed.), Escherichia coli Salmonella:
47.   Hoffman, L. M., J. J. Jendrisak, R. J. Meis,  Y. Goryshin, W. S.               cellular molecular biology. ASM Press, Washington, D.C.
      Reznikoff. 2000. Transposome insertional mutagenesis direct sequenc-         74. Raffaelli, N., T. Lorenzi, P. L. Mariani, M. Emanuelli,  Amici, S. Rug-
      ing microbial genomes. Genetica 108:19â€“24.                                        gieri, G. Magni. 1999. Escherichia coli NadR regulator endowed
48.   Hughes, K. T., D. Ladika, J. R. Roth, B. M. Olivera. 1983. indis-             nicotinamide mononucleotide adenylyltransferase activity. J. Bacteriol.
      pensable gene NAD biosynthesis Salmonella typhimurium. J. Bacte-              181:5509â€“5511.
      riol. 155:213â€“221.                                                               75. Reich, K. , L. Chovan, P. Hessler. 1999. Genome scanning Hae-
 4572        GERDES ET AL.                                                                                                                               J. BACTERIOL.

      mophilus influenzae identification essential genes. J. Bacteriol. 181:    90. Thompson, J. D., D. G. Higgins, T. J. Gibson. 1994. Clustal-W: im-
      4961â€“4968.                                                                           proving sensitivity progressive multiple sequence alignment 76.   Reidl, J., S. Schlor,  Kraiss, J. Schmidt-Brauns, G. Kemmer, E.                sequence weighting, position-specific gap penalties weight matrix
      Soleva. 2000. NADP NAD utilization Haemophilus influenzae. Mol.               choice. Nucleic Acids Res. 22:4673â€“4680.
      Microbiol. 35:1573â€“1581.                                                         91. Timberlake, W., V. Gavrias. November 1999. Identification essential
77.   Rosamond, L.,  Allsop. 2000. Harnessing power genome             survival genes. U.S. patent 5,976,828.
      search new antibiotics. Science 287:1973â€“1976.                           92. Tritz, G. J. 1974. Characterization nadR locus Escherichia coli.  J.
78.   Santos, M. ,  Jimenez, J. L. Revuelta. 2000. Molecular character-            Microbiol. 20:205â€“209.
      ization FMN1, structural gene monofunctional flavokinase       93. Vallari, D. S., C. O. Rock. 1985. Isolation characterization       Saccharomyces cerevisiae. J. Biol. Chem. 275:28618â€“28624.                            Escherichia coli pantothenate permease (panF) mutants. J. Bacteriol. 164:
79.   Schmid, M. B. 1998. Novel approaches discovery antimicrobial
                                                                                           136â€“142.
      agents. Curr. Opin. Chem. Biol. 2:529â€“534.
                                                                                       94. Vallari, D. S., C. O. Rock. 1987. Isolation characterization 80.   Schweiger, M., K. Hennig, F. Lerner, M. Niere, M. Hirsch-Kauffmann, T.
                                                                                           temperature-sensitive pantothenate kinase (coaA) mutants Escherichia
      Specht, C. Weise, S. L. Oei, M. Ziegler. 2001. Characterization       recombinant human nicotinamide mononucleotide adenylyl transferase                   coli. J. Bacteriol. 169:5795â€“5800.
      (NMNAT), nuclear enzyme essential NAD synthesis. FEBS Lett.                95. Waibel, , T. Hanazawa, G. Hinton, K. Shikano, K. J. Lang. 1989.
      492:95â€“100.                                                                          Phoneme recognition using time-delay neural networks. IEEE Transact.
81.   Scorpio, , Y. Zhang. 1996. Mutations pncA, gene encoding                  Acoustics Speech Signal Process. 37:328â€“339.
      pyrazinamidase/nicotinamidase, cause resistance antituberculous           96. Wang, H., W. Huang, Y.-J. Fei, H. Xia, T. L. Yang-Feng, F. H. Leibach, L. D.
      drug pyrazinamide tubercle bacillus. Nat. Med. 2:662â€“667.                         Devoe, V. Ganapathy, P. D. Prasad. 1999. Human placental Naâ«¹-
82.   Selkov, E., N. Maltsev, G. J. Olsen, R. Overbeek, W. B. Whitman. 1997.           dependent multivitamin transporter. Cloning, functional expression, gene
      reconstruction metabolism Methanococcus jannaschii                  structure, chromosomal location. J. Biol. Chem. 274:14875â€“14883.
      sequence data. Gene 197:GC11â€“GC26.                                               97. Wang, L. L.,